GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Multiple Sclerosis and Related Disorders - Volume 4, Issue 4, July 2015, Pages 370-376

Jerry S. Wolinsky, T. Erik Borresen, Dennis W Dietrich, Daniel Wynn, Yulia Sidi, Joshua R. Steinerman, Volker Knappertz, Scott Kolodny, on behalf of the GLACIER Study Group on behalf of the GLACIER Study Group,